Exclusive interview with Cinfa Biotech GmbH released ahead of Biosimilars and Biobetters

This year's conference will address the latest regulatory updates, pharmacovigilance of biosimilars, patent litigation, market access and global market developments. End Quote

(1888PressRelease) August 01, 2015 - Following this week's breaking news in the US Biosimilars and Biobetters market, the European players are eager to hear updates from the regulators, as well as projects from mid-sized pharma. Against this backdrop, SMi's 6th annual Biosimilars and Biobetters conference, taking place 30th September - 1st October 2015 in London, will provide an ideal and timely platform to engage in such scientific and commercial discussions.

Unique perspectives will be shared and debated on:
• Evolving biosimilar regulatory landscape
• Market access and product commercialisation barriers
• Global marketing developments, including a focus on emerging market trends
• In-depth protein characterisation and analytical comparability to efficiently and effectively collect data

When asked about what his presentation 'Clinical Development Strategies for Biosimilars - A Mid-Size Pharma Perspective' will offer, Karsten Roth, Director Clinical Operations from Cinfa Biotech GmbH said:
"Attendees will take away from my presentation insight on a new approach for the clinical development of Biosimilars, aligned with national health authorities and central EMA advice"

Furthermore when asked about the conference programme as a whole, Karsten said:
"The conference programme has a good balance of speakers from the regulators and industry; I am especially looking forward to hearing more about the regulatory view on guideline updates"

Read the full interviews with Cinfa Biotech GmbH, Harvest Moon Pharmaceuticals USA, Inc. and Schwegman, Lundberg & Woessner at http://www.biosimilars-biobetters.co.uk/1888pressrelease

Speaker Panel includes:
• Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc.
• Shahin Kauser, Senior Scientific Assessor, MHRA
• Chris Teale, Vice President Europe, GfK NOP Ltd
• Bracha Timan, Director, Israel Site Head, Global Bioassays & Technology, Global R&D, Teva
• Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
• Karsten Roth, Director Clinical Operations, Cinfa Biotech GmbH
• Alan Sheppard, Principal, Global Generics and Biosimilars, IMS Health
• Steinar Madsen, Medical Director, Norwegian Medicines Agency

To view the full speaker line-up and complete conference programme, visit http://www.biosimilars-biobetters.co.uk/1888pressrelease

###

space

Other Related Press Releases